Highlights

  • Vitrafy Life Sciences has secured firm commitments for a A$30 million institutional placement.
  • The placement was completed at an offer price of A$2.60 per share.
  • Approximately 11.54 million new shares will be issued under the raising.
  • Eligible shareholders will have the opportunity to participate in a Share Purchase Plan (SPP) targeting up to A$2 million.
  • Funds will be used to increase Guardion device manufacturing, support US expansion and provide working capital.

Vitrafy Life Sciences Ltd (ASX:VFY) has announced the successful completion of a A$30 million institutional placement, securing support from both existing and new institutional and sophisticated investors. The capital raising follows the company's recent update regarding progress in the US blood market and is intended to support manufacturing expansion, commercial growth initiatives and operational development.

The company confirmed that firm commitments have been received for the non-underwritten placement, which was conducted at an offer price of A$2.60 per share. Alongside the institutional raising, Vitrafy also plans to launch a Share Purchase Plan that could raise an additional A$2 million from eligible shareholders in Australia and New Zealand.

Vitrafy shares were trading at AUD 3.50 during the afternoon session on 12 June 2026, down 7.89% for the day. Despite the decline, the stock remains higher by 141.38% over the past 12 months, reflecting a gain of AUD 2.05 during that period.

Fresh Capital to Support Commercial Growth Initiatives

The newly raised capital is expected to play a significant role in supporting Vitrafy's next phase of growth.

According to the company, proceeds from the placement will primarily be directed towards increasing the manufacturing of its Guardion cryopreservation devices to meet anticipated demand. Additional funding will be allocated to accelerating sales and operational activities in the United States, which remains a strategic market for the business.

The company also intends to use part of the proceeds for general working capital requirements and to cover costs associated with the placement and Share Purchase Plan.

Management indicated that recent progress in the US blood market contributed to investor interest in the capital raising. The company stated that it has become increasingly confident about growth opportunities available within the sector as it continues progressing commercialisation and medical device registration objectives.

Placement Raises A$30 Million

The institutional placement will raise gross proceeds of A$30 million through the issue of approximately 11,538,462 new fully paid ordinary shares.

These new shares will be issued at A$2.60 per share and will rank equally with existing ordinary shares from their date of issue.

Vitrafy noted that the offer price represented a 31.6% discount to the company's last closing price of A$3.80 per share on 9 June 2026. The offer price also reflected an 8.8% discount to the 15-day volume weighted average price of A$2.851 up to and including 9 June 2026.

The company stated that the placement was completed using existing placement capacities available under ASX Listing Rules 7.1 and 7.1A, meaning shareholder approval was not required.

Of the total shares being issued, approximately 5.15 million shares will be issued under Listing Rule 7.1 capacity, while around 6.38 million shares will be issued under Listing Rule 7.1A capacity.

Management Highlights Confidence in Growth Opportunities

Commenting on the capital raising, Managing Director and Chief Executive Officer Brent Owens said recent commercial milestones in the US blood market had strengthened confidence regarding future growth opportunities.

Management indicated that the additional capital would support scaling of Guardion manufacturing capabilities to address expected demand levels. The funding is also expected to help accelerate the expansion of US operations as the company works toward commercialisation and medical device registration milestones.

The company also acknowledged the support received from both existing and new investors who participated in the raising.

The successful completion of the placement provides Vitrafy with additional financial resources as it continues executing its broader business strategy focused on cryopreservation technologies and healthcare solutions.

Share Purchase Plan Offers Additional Participation Opportunity

In addition to the institutional placement, Vitrafy announced plans to launch a Share Purchase Plan for eligible retail shareholders.

The SPP aims to raise up to A$2 million and will be offered on the same pricing terms as the institutional placement.

Eligible shareholders with registered addresses in Australia or New Zealand as of 7:00pm AEST on 11 June 2026 will be able to apply for up to A$30,000 worth of new shares. Applications under the SPP will be free from brokerage, commission and other transaction costs.

Shares issued under the SPP will also be priced at A$2.60 per share and will rank equally with existing ordinary shares.

The company stated that the SPP is not underwritten and will be capped at A$2 million. Vitrafy also retains discretion to scale back applications if demand exceeds the targeted raising amount.

According to the indicative timetable, the SPP offer booklet is expected to be dispatched on 19 June 2026, with the offer scheduled to close on 3 July 2026. Results are expected to be announced on 8 July 2026, followed by settlement and allotment on 9 July 2026.

Funding Supports Expansion of Proprietary Technology Platform

Vitrafy operates within the healthcare and life sciences sector, focusing on cryopreservation technologies designed to preserve sensitive biological materials.

The company has developed a proprietary cryopreservation ecosystem that includes its Guardion cryopreservation freezing unit and Lifechain™, a cloud-based software platform.

Together, these technologies are designed to provide an integrated cryopreservation solution that supports the collection, storage and delivery of biological materials.

Vitrafy states that its technology platform aims to improve the quality and integrity of preserved biomaterials while providing greater reliability and efficiency throughout the cryopreservation process.

As demand for advanced biological storage and preservation solutions continues to evolve, the company has been working to expand its commercial footprint and strengthen its position within international healthcare markets.

Institutional Support Highlights Investor Interest

The placement received backing from both new and existing institutional and sophisticated investors.

The capital raising was advised by a joint lead manager syndicate comprising Bell Potter Securities Limited, Jarden Australia Pty Ltd and Morgans Corporate Limited.

Institutional participation in the placement provides Vitrafy with access to capital required for executing planned growth initiatives while also broadening engagement with professional investors.

The successful completion of the raising provides additional resources to support manufacturing expansion and operational scaling activities at a time when the company is pursuing opportunities in the US market.

What Does This Mean for Investors?

Vitrafy's latest announcement strengthens its funding position through a A$30 million institutional placement, with the possibility of raising an additional A$2 million through a Share Purchase Plan.

The capital will be directed towards increasing Guardion device manufacturing capacity, supporting expansion of US operations, funding sales and marketing initiatives, and meeting working capital requirements.

The placement follows recent developments in the US blood market, which management highlighted as an area of growing opportunity. Investors may now focus on how the company deploys the newly raised capital, progresses commercialisation activities and advances medical device registration milestones in the United States.